Impact of the SARS-CoV-2 Epidemic on Lung Cancer Surgery in France: A Nationwide Study.

Fiche publication

Date publication

décembre 2021

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BERNARD Alain , Dr PAGES Pierre-Benoit , Pr QUANTIN Catherine , Pr BONNIAUD Philippe

Tous les auteurs :
Pages PB, Cottenet J, Bonniaud P, Tubert-Bitter P, Piroth L, Cadranel J, Bernard A, Quantin C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34944896

Résumé

Few studies have investigated the link between SARS-CoV-2 and health restrictions and its effects on the health of lung cancer (LC) patients. The aim of this study was to assess the impact of the SARS-CoV-2 epidemic on surgical activity volume, postoperative complications and in-hospital mortality (IHM) for LC resections in France. All data for adult patients who underwent pulmonary resection for LC in France in 2020, collected from the national administrative database, were compared to 2018-2019. The effect of SARS-CoV-2 on the risk of IHM and severe complications within 30 days among LC surgery patients was examined using a logistic regression analysis adjusted for age, sex, comorbidities and type of resection. There was a slight decrease in the volume of LC resections in 2020 ( = 11,634), as compared to 2018 ( = 12,153) and 2019 ( = 12,227), with a noticeable decrease in April 2020 (the peak of the first wave of epidemic in France). We found that SARS-CoV-2 (0.43% of 2020 resections) was associated with IHM and severe complications, with, respectively, a sevenfold (aOR = 7.17 (3.30-15.55)) and almost a fivefold (aOR = 4.76 (2.31-9.80)) increase in risk. Our study suggests that LC surgery is feasible even during a pandemic, provided that general guidance protocols edited by the surgical societies are respected.